CONCLUSION

Kidney imaging is poised to revolutionize nephrology’s diagnostic and treatment paradigms. Whether it’s CKD, DKD, hypertensive nephrosclerosis, or kidney transplantation, quantitative imaging biomarkers provide direct, repeatable, and noninvasive insights into tissue-level pathology, including fibrosis, hypoxia, perfusion, lipid infiltration, and microvascular compromise, which traditional clinical measures are unable to detect. Customized therapy monitoring, focused treatments, and early risk assessment are made possible by these modalities. Advanced technologies such as H-scan, radiomics, PAI, and AI-driven analysis have markedly enhanced renal imaging. Collectively, hypoxia-sensitive BOLD, flow-sensitive ASL, micro-structural IVIM, stiffness-oriented SWE/MRE, native T1-mapping and vascular Doppler indices detect injury before traditional markers rise, stratify fast vs. slow progressors more accurately than eGFR or albuminuria alone and can be modulated by targeted therapy within days to months, laying the foundation for precision nephrology that individualizes risk prediction, therapeutic titration, and early assessment of drug efficacy. These technologies broaden their applications from diagnostics to prognostication and therapy optimization. The efficacy of imaging-based surrogate endpoints is limited by the need for standardization, integration into clinical workflows, regulatory acknowledgment, and longitudinal validation.

Despite advances in renal imaging, evidence that imaging-guided management directly slows CKD progression or reduces cardiovascular events is still limited. Future prospective studies are needed to establish the clinical and economic impact of imaging-guided strategies.

Future kidney imaging research should prioritize multicenter longitudinal trials, imaging-informed clinical trials, integration with multi-omics and digital health platforms, establishment of imaging thresholds associated with hard outcomes, and implementation science to enhance accessibility, cost-effectiveness, and guideline inclusion. Renal imaging is now a crucial component of precision nephrology, linking pathophysiology to tailored treatment plans thanks to recent developments.